Cargando…

Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis

BACKGROUND: Safety and effectiveness outcomes in Multiple Sclerosis (MS) patients receiving different disease-modifying therapies (DMT) and different types of vaccines against SARS-CoV-2 are limited. Growing evidence coming mainly from Israel, Europe and North America using mRNA and adenoviral vecto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciampi, Ethel, Uribe-San-Martin, Reinaldo, Soler, Bernardita, García, Lorena, Guzman, Jorge, Pelayo, Carolina, Jürgensen, Lukas, Guzman, Ignacio, Vera, Francisco, Galleguillos, Lorna, Cárcamo, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842089/ https://www.ncbi.nlm.nih.gov/pubmed/35182880 http://dx.doi.org/10.1016/j.msard.2022.103690

Ejemplares similares

COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile
por: Ciampi, Ethel, et al.
Publicado: (2020)

COVID-19 in MS and NMOSD: A multicentric online national survey in Chile
por: Ciampi, Ethel, et al.
Publicado: (2020)

Frontoparietal connectivity correlates with working memory performance in multiple sclerosis
por: Figueroa-Vargas, Alejandra, et al.
Publicado: (2020)

Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial
por: Ciampi, Ethel, et al.
Publicado: (2020)

Th1 and Th17 Cells and Associated Cytokines Discriminate among Clinically Isolated Syndrome and Multiple Sclerosis Phenotypes
por: Arellano, Gabriel, et al.
Publicado: (2017)

Characterization of relapsing-remitting multiple sclerosis patients using support vector machine classifications of functional and diffusion MRI data
por: Zurita, Mariana, et al.
Publicado: (2018)

mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: Humoral responses and protectivity—Does it matter?
por: Tütüncü, Melih, et al.
Publicado: (2023)

Galectin-8 as an immunosuppressor in experimental autoimmune encephalomyelitis and a target of human early prognostic antibodies in multiple sclerosis
por: Pardo, Evelyn, et al.
Publicado: (2017)

Key points to keep in mind related to COVID-19 vaccines in people with multiple sclerosis
por: Galleguillos, Lorna, et al.
Publicado: (2021)

COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: Insight to the immune response after COVID
por: Fiorella, Celsi, et al.
Publicado: (2020)

Assessment and Impact of Cognitive Impairment in Multiple Sclerosis: An Overview
por: Macías Islas, Miguel Ángel, et al.
Publicado: (2019)

Gelastic epilepsy: Beyond hypothalamic hamartomas
por: Uribe-San-Martin, Reinaldo, et al.
Publicado: (2015)

Editorial: Women in multiple sclerosis and other demyelinating disorders: A global perspective
por: Ciampi, Ethel, et al.
Publicado: (2023)

LGI1-antibody associated epilepsy successfully treated in the outpatient setting
por: Uribe-San-Martín, R., et al.
Publicado: (2020)

Acute to Chronic Electro-Clinical Manifestations of Neuro-COVID and the Long-Haul Consequences in People With Epilepsy: A Review
por: Milan, Anna, et al.
Publicado: (2022)

Characterization of humoral response to COVID mRNA vaccines in multiple sclerosis patients on disease modifying therapies
por: Ali, Ahya, et al.
Publicado: (2021)

Humoral response to mRNA vaccines against SARS-CoV-2 in patients with humoral immunodeficiency disease
por: Bitzenhofer, Michaela, et al.
Publicado: (2022)

Impacto psicosocial en la vida del paciente quemado y su afrontamiento :
por: Guzmán Cárcamo, Jocelyn Edith
Publicado: (2005)

Humoral response to SARS-CoV-2 mRNA vaccine in patients with multiple sclerosis treated with natalizumab
por: Capuano, Rocco, et al.
Publicado: (2021)

Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
por: Dominelli, Federica, et al.
Publicado: (2022)

Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America
por: Steinberg, Judith, et al.
Publicado: (2019)

Preliminary evidence of blunted humoral response to SARS-Cov-2 (MRNA) vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Coronavirus disease 2019 in Latin American patients with multiple sclerosis
por: Fragoso, Yara D., et al.
Publicado: (2021)

Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple Sclerosis
por: Breu, Markus, et al.
Publicado: (2023)

Humoral immune activation in amyotrophic lateral sclerosis patients
por: Rentzos, Michael, et al.
Publicado: (2013)

Real-world experience of ocrelizumab in multiple sclerosis patients in Latin America
por: ROJAS, Juan Ignacio, et al.
Publicado: (2021)

Long-Term Dynamic Humoral Response to SARS-CoV-2 mRNA Vaccines in Patients on Peritoneal Dialysis
por: Quiroga, Borja, et al.
Publicado: (2022)

INACTIVATION OF ENDOTOXIN BY A HUMORAL COMPONENT : II. INTERACTION OF ENDOTOXIN WITH SERUM AND PLASMA
por: Skarnes, Robert C., et al.
Publicado: (1958)

Humoral response of the mRNA-1273 SARS-CoV-2 vaccine in peritoneal dialysis patients
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2021)

Preliminary evidence of blunted humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated with ocrelizumab
por: Gallo, Antonio, et al.
Publicado: (2021)

Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Achiron, Anat, et al.
Publicado: (2021)

Six-month humoral response to mRNA SARS-CoV-2 vaccination in patients with multiple sclerosis treated with ocrelizumab and fingolimod
por: Capuano, Rocco, et al.
Publicado: (2022)

Study of humoral and cellular immunity in vaccinated with mRNA‐1273
por: Gutiérrez‐Bautista, Juan Francisco, et al.
Publicado: (2022)

A Study on Instructional Humor: How Much Humor Is Used in Presentations?
por: Shoda, Vera Paola, et al.
Publicado: (2021)

Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis()
por: Novak, Frederik, et al.
Publicado: (2021)

Six-month humoral response to BNT162b2 mRNA COVID-19 vaccine in people with multiple sclerosis treated with natalizumab
por: Altieri, Manuela, et al.
Publicado: (2022)

Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
por: Achtnichts, Lutz, et al.
Publicado: (2021)

Correspondence to: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Piquet, Amanda L., et al.
Publicado: (2021)

Correspondence: Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies
por: Petereit, Hela-Felicitas, et al.
Publicado: (2021)

SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
por: Meyer-Arndt, Lil, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fshv743sm5hq73cpap5j6jhuit